Welcome to our dedicated page for Vistagen Therapeutics news (Ticker: VTGN), a resource for investors and traders seeking the latest updates and insights on Vistagen Therapeutics stock.
Vistagen Therapeutics, Inc. develops late clinical-stage biopharmaceutical programs based on nose-to-brain neurocircuitry and intranasal pherine product candidates. Company news centers on fasedienol nasal spray for the acute treatment of social anxiety disorder, including PALISADE Phase 3 study updates, and refisolone nasal spray for vasomotor symptoms due to menopause.
Recurring updates also cover FDA and IND communications, clinical data from psychiatric and neurological programs, fiscal results, cash-management actions, executive and board changes, and healthcare investor conference presentations. The company’s pipeline is described around investigational intranasal candidates for indications that include social anxiety disorder, major depressive disorder, and menopausal hot flashes.
VistaGen Therapeutics (NASDAQ: VTGN) announced its inclusion in the Russell 2000® Index effective June 28, 2021. This milestone is expected to enhance the company's visibility within the investment community, according to CEO Shawn K. Singh. The Russell 2000 Index is a widely recognized benchmark for small-cap companies, and its annual reconstitution considers approximately 4,000 U.S. stocks ranked by market capitalization. This move aims to introduce VistaGen to a broader investor audience as it advances its late-stage programs for anxiety and depression treatment.
VistaGen Therapeutics (NASDAQ: VTGN) has initiated its PALISADE-1 Phase 3 trial for PH94B, a nasal spray aimed at treating Social Anxiety Disorder (SAD). This randomized, double-blind, placebo-controlled study will assess the safety and efficacy of PH94B, which has received FDA Fast Track designation. The trial, involving 200 participants across 18 sites in the U.S., aims to confirm positive results seen in Phase 2 trials. Topline results are expected by mid-2022, with the potential to offer a rapid-acting treatment option for over 23 million Americans suffering from SAD.
VistaGen Therapeutics (NASDAQ: VTGN) announced its participation in two upcoming investor conferences in June 2021. The Jefferies Virtual Healthcare Conference will take place on June 2 at 2:30 p.m. ET, while the William Blair 41st Annual Virtual Growth Stock Conference is scheduled for June 3 at 3:00 p.m. ET. Both conferences will feature webcasts available for attendees. VistaGen focuses on developing innovative medications for anxiety, depression, and other CNS disorders. For more details, visit www.vistagen.com.
VistaGen Therapeutics has appointed Ann Cunningham as Chief Commercial Officer, enhancing its leadership team. With over 25 years of pharmaceutical experience, Cunningham has been involved in successful marketing strategies for neuropsychiatric products. Her expertise will support VistaGen's pre-commercial efforts for PH94B, aimed at treating social anxiety disorder. Cunningham's prior role on VistaGen's Board since January 2019 positions her well to drive brand awareness and market entry for the company’s CNS drug candidates. The transition reflects VistaGen's focus on expanding its commercial capabilities.
VistaGen Therapeutics (NASDAQ: VTGN) announced the appointment of Dr. Joanne Curley to its Board of Directors, expanding the board to seven members. With over 25 years of experience, including prior roles at Gilead Sciences and Vera Therapeutics, Dr. Curley has a track record of advancing multiple products through regulatory approvals. Her expertise in drug development aligns with VistaGen's mission to innovate treatments for anxiety and depression, enhancing leadership and strategic direction.
VistaGen Therapeutics (NASDAQ: VTGN) presented key data on its Phase 3 drug candidate PH94B, an investigational nasal spray for treating social anxiety disorder (SAD). The data revealed PH94B's unique mechanism of action, differentiating it from traditional benzodiazepines. PH94B showed no significant effect on GABA potentiation and provided rapid anti-anxiety effects without sedation, indicating a safer profile. With approximately 20 million Americans affected by SAD, this innovative treatment could offer a new standard of care amid increasing concerns over benzodiazepine safety risks. Phase 3 development is set to commence soon.
VistaGen Therapeutics (NASDAQ: VTGN) announced participation in two investor conferences in March. The first is the Maxim Group and M-Vest’s Inaugural Emerging Growth Virtual Conference from March 17-19, featuring a corporate presentation and a fireside chat on March 19 at 1:00 p.m. ET. The second conference, the Benzinga Biotech Small Cap Conference, is on March 25 at 10:05 a.m. ET. VistaGen aims to develop innovative treatments for anxiety, depression, and central nervous system disorders. More details can be found on the respective conference websites.
VistaGen Therapeutics (NASDAQ: VTGN) has released promising preclinical data for PH10, a Phase 2 investigational pherine nasal spray targeting major depressive disorder (MDD). Unlike traditional antidepressants, PH10's mechanism does not involve GABA-A receptor activation, potentially reducing common side effects. MDD affects over 264 million globally, with the current market dominated by SSRIs and SNRIs, which have slow onset and multiple side effects. With the growing need for effective MDD treatments, PH10 may offer a rapid-onset, stand-alone alternative, addressing concerns raised in FDA communications regarding benzodiazepines.
VistaGen Therapeutics (NASDAQ: VTGN) reported a net loss of $5.65 million for the third quarter of fiscal 2021, down from $6.28 million in the previous year. The company recognized $313,600 in sublicense revenue from its agreement with EverInsight Therapeutics, a significant increase compared to none in the prior year. VistaGen closed a $100 million public offering to strengthen its balance sheet, enabling the launch of pivotal Phase 3 studies for PH94B targeting anxiety disorders, among other clinical trials. Cash and equivalents stood at $104.3 million as of December 31, 2020.
VistaGen Therapeutics, Inc. (NASDAQ: VTGN) has regained compliance with Nasdaq's minimum bid price requirement as of January 5, 2021. The company previously received a notice on January 31, 2020, regarding non-compliance due to a bid price below $1.00 for 30 consecutive business days. VistaGen met the requirement by maintaining a closing bid price of $1.00 or more for 10 consecutive trading days, starting January 4, 2021. VistaGen is now compliant with all Nasdaq listing standards, and the matter is considered closed by Nasdaq.